GE / EN / RU

Signatera — detection of circulating tumor DNA in the blood


Monitoring disease progression and the effectiveness of cancer treatment

Signatera Signatera is a personalized circulating tumor DNA (ctDNA) test used in oncology monitoring and assessment of molecular residual disease (MRD).

ctDNA can be a useful biomarker for:

  • Early detection of recurrence.
  • Risk stratification after surgery or chemotherapy.
  • Supporting decisions about treatment initiation and duration.
  • Monitoring the effectiveness of therapy.

Signatera A personalized tumor-informed ctDNA assay

SignateraThe test is optimized to detect extremely low quantities of circulating tumor DNA (ctDNA) and to determine the presence or absence of molecular residual disease (MRD). It can detect as little as one genomic equivalent of tumor ctDNA in 10 mL of blood (VAF = 0.01%).

The assay uses personalized ultra-deep multiplex PCR-based next-generation sequencing (NGS).

Main testing stages

  1. Whole-exome sequencing of tumor tissue, analysis and filtering of patient-specific somatic mutations, and selection of 16 highly specific individual clonal somatic mutations.
    Sample required: Tumor tissue preserved in a paraffin block.
  2. Development of a personalized panel for each patient based on these 16 clonal mutations, followed by longitudinal sequencing of blood samples to quantify circulating tumor DNA (ctDNA).

High potential Signatera has been studied in the following cancers:

  • Lung cancer
  • Colorectal cancer
  • Invasive bladder cancer
  • Breast cancer (all types).
In the validation studies cited on the original site, cancer recurrence was detected by Signatera on average:

  • In colorectal cancer: 8.7 months before the first clinical recurrence.
  • In breast cancer: 9.5 months before the first clinical recurrence.
  • In muscle-invasive bladder cancer: 2.8 months before the first clinical recurrence.

How is the test performed?

STAGE 1.    Biological material: Paraffin block and/or histological slide

STAGE 2.      Venous blood collected in an EDTA tube

STAGE 3.    Analysis and creation of an individualized tumor profile

STAGE 4.      Reporting whether tumor ctDNA is detected in the bloodstream

STAGE 5.  Follow-up testing every 6–12 months (venous blood in an EDTA tube).

Initial test price (stages 1–4): For pricing information, please contact our consultant.
Sample required: Paraffin-embedded tumor tissue and venous EDTA blood

Cost of each follow-up test (stage 5): For pricing information, please contact our consultant.
Sample required: Venous blood in an EDTA tube

Have a question?

Let us discuss it. Complete the form and our specialist will answer your questions.

We serve patients across Georgia!

Send an enquiry
Get in touchMessage on WhatsApp

Please do not send medical information or test results through this form.